Barriers to clinical adoption of pharmacogenomic testing in psychiatry: a critical analysis.

ABSTRACT: Pharmacogenomics (PGx) is the study of genetic influences on an individual's response to medications. Improvements in the quality and quantity of PGx research over the past two decades have enabled the establishment of commercial markets for PGx tests. Nevertheless, PGx testing has yet to be adopted as a routine practice in clinical care. Accordingly, policy regulating the commercialization and reimbursement of PGx testing is in its infancy. Several papers have been published on the topic of challenges, or 'barriers' to clinical adoption of this healthcare innovation. However, many do not include recent evidence from randomized controlled trials, economic utility studies, and qualitative assessments of stakeholder opinions. The present paper revisits the most cited barriers to adoption of

SUBMITTER: Virelli CR 

PROVIDER: S-EPMC8492820 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature